Luteal supplementation in in vitro fertilization: More questions than answers

被引:47
作者
Hubayter, Ziad R. [1 ]
Muasher, Suheil J. [1 ,2 ,3 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Gynecol & Obstet, Div Reprod Endocrinol & Infertil, Baltimore, MD 21205 USA
[2] George Washington Univ, Dept Obstet & Gynecol, Washington, DC USA
[3] Virginia Commonwealth Univ, Dept Obstet & Gynecol, Richmond, VA USA
关键词
luteal phase supplementation; in vitro fertilization; progesterone; estradiol; human chorionic gonadotropin; gonadotropin-releasing hormone agonists and antagonists;
D O I
10.1016/j.fertnstert.2008.02.095
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To update clinicians on different regimens of luteal phase supplementation in IVF-stimulated cycles and to identify areas that need further research in this subject. Design: Literature review and critical analysis of published studies on luteal phase supplementation during the last 20 years. Conclusion(S): Luteal phase supplementation in IVF-stimulated cycles, both in gonadotropin releasing hormone agonist and antagonist protocols, is considered an essential requirement for optimal success rates. The date of initiation and discontinuation of supplemented hormones is not adequately studied in the literature. In most major controlled and randomized studies, there are no significant differences in success rates with progesterone supplementation alone, progesterone and estradiol, progesterone and human chorionic gonadotropin, and human chorionic gonadotropin alone. Success rates seem similar with intramuscular and vaginal progesterone administration with patient preference for the vaginal route. The optimal dose of progesterone has not been studied in a scientific way in the literature. The use of gonadotropin releasing hormone agonists for luteal phase supplementation in antagonist cycles appears to be promising, and is worthy of further investigation.
引用
收藏
页码:749 / 758
页数:10
相关论文
共 79 条
[1]  
Abate A., 1999, Clinical and Experimental Obstetrics and Gynecology, V26, P203
[2]   Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates [J].
Acevedo, Belen ;
Gomez-Palomares, Jose Luis ;
Ricciarelli, Elisabetta ;
Hernandez, Eleuterio R. .
FERTILITY AND STERILITY, 2006, 86 (06) :1682-1687
[3]   GnRH antagonist in assisted reproduction: a Cochrane review [J].
Al-Inany, H ;
Aboulghar, M .
HUMAN REPRODUCTION, 2002, 17 (04) :874-885
[4]   The luteal phase of nonsupplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist Cetvorelix [J].
Albano, C ;
Grimbizis, G ;
Smitz, J ;
Riethmüller-Winzen, H ;
Reissmann, T ;
Van Steirteghem, A ;
Devroey, P .
FERTILITY AND STERILITY, 1998, 70 (02) :357-359
[5]   Progesterone supplementation during early gestations after IVF or ICSI has no effect on the delivery rates: a randomized controlled trial [J].
Andersen, AN ;
Popovic-Todorovic, B ;
Schmidt, KT ;
Loft, A ;
Lindhard, A ;
Hojgaard, A ;
Ziebe, S ;
Hald, F ;
Hauge, B ;
Toft, B .
HUMAN REPRODUCTION, 2002, 17 (02) :357-361
[6]  
[Anonymous], HUMAN REPROD
[7]  
Anserini P, 2001, Minerva Ginecol, V53, P297
[8]   PROSPECTIVE RANDOMIZED COMPARISON OF HUMAN CHORIONIC-GONADOTROPIN VERSUS INTRAMUSCULAR PROGESTERONE FOR LUTEAL-PHASE SUPPORT IN ASSISTED REPRODUCTION [J].
ARAUJO, E ;
BERNARDINI, L ;
FREDERICK, JL ;
ASCH, RH ;
BALMACEDA, JP .
JOURNAL OF ASSISTED REPRODUCTION AND GENETICS, 1994, 11 (02) :74-78
[9]   A COMPARATIVE, RANDOMIZED STUDY OF 3 DIFFERENT PROGESTERONE SUPPORT OF THE LUTEAL-PHASE FOLLOWING IVF/ET PROGRAM [J].
ARTINI, PG ;
VOLPE, A ;
ANGIONI, S ;
GALASSI, MC ;
BATTAGLIA, C ;
GENAZZANI, AR .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1995, 18 (01) :51-56
[10]   Effects of vaginal progesterone administration starting on the day of oocyte retrieval on pregnancy rates [J].
Baruffi, R ;
Mauri, AL ;
Petersen, CG ;
Felipe, V ;
Franco, JG .
JOURNAL OF ASSISTED REPRODUCTION AND GENETICS, 2003, 20 (12) :517-520